|
US11077101B1
(en)
|
2018-07-18 |
2021-08-03 |
Tango Therapeutics, Inc. |
Compounds and methods of use
|
|
MX2021006841A
(es)
|
2018-12-10 |
2021-07-02 |
Ideaya Biosciences Inc |
Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
|
|
WO2021086879A1
(en)
|
2019-10-28 |
2021-05-06 |
Tango Therapeutics, Inc. |
Compounds and methods of use
|
|
EP4188920A1
(en)
|
2020-07-31 |
2023-06-07 |
Tango Therapeutics, Inc. |
Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
|
|
KR20240019172A
(ko)
*
|
2021-06-02 |
2024-02-14 |
아이디어야 바이오사이언시스 인코포레이티드 |
Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법
|
|
EP4458812A1
(en)
*
|
2021-12-27 |
2024-11-06 |
Medshine Discovery Inc. |
Pyrazole-1(2h)-phthalazinone compound and application thereof
|
|
US20250171432A1
(en)
*
|
2022-01-26 |
2025-05-29 |
Tango Therapeutics, Inc. |
Compounds and methods of use
|
|
WO2023202626A1
(zh)
*
|
2022-04-22 |
2023-10-26 |
北京望实智慧科技有限公司 |
稠和哒嗪酮化合物作为prmt5抑制剂
|
|
WO2023246873A1
(zh)
*
|
2022-06-23 |
2023-12-28 |
南京明德新药研发有限公司 |
氨基取代的杂芳基衍生物及其应用
|
|
EP4549442A1
(en)
*
|
2022-07-01 |
2025-05-07 |
Cytosinlab Therapeutics Co., Ltd. |
Prmt5 inhibitors and use thereof
|
|
WO2024027703A1
(zh)
*
|
2022-08-02 |
2024-02-08 |
上海艾力斯医药科技股份有限公司 |
一种prmt5抑制剂、其制备方法及应用
|
|
JP2026508792A
(ja)
*
|
2022-10-25 |
2026-03-13 |
タンゴ セラピューティクス， インコーポレイテッド |
結晶形態、医薬組成物、及びその使用方法
|
|
CN120265615A
(zh)
*
|
2022-11-29 |
2025-07-04 |
正大天晴药业集团股份有限公司 |
含有二氢酞嗪的化合物
|
|
WO2024118943A2
(en)
*
|
2022-11-30 |
2024-06-06 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
|
|
TW202440126A
(zh)
*
|
2022-11-30 |
2024-10-16 |
美商安進公司 |
利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
|
|
EP4644389A1
(en)
*
|
2022-12-30 |
2025-11-05 |
Suzhou Puhe Biopharma Co., Ltd. |
Prmt5-mta inhibitor
|
|
EP4653435A1
(en)
*
|
2023-01-17 |
2025-11-26 |
Suzhou Puhe Biopharma Co., Ltd. |
Prmt5-mta inhibitor
|
|
EP4694892A1
(en)
*
|
2023-04-13 |
2026-02-18 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor
|
|
CN121175299A
(zh)
*
|
2023-04-28 |
2025-12-19 |
智擎生技制药股份有限公司 |
Mta协同性prmt5抑制剂
|
|
CN121712509A
(zh)
|
2023-05-04 |
2026-03-20 |
锐新医药公司 |
用于ras相关疾病或病症的组合疗法
|
|
CN116283800B
(zh)
*
|
2023-05-16 |
2023-07-18 |
英矽智能科技(上海)有限公司 |
氧代喹唑啉类化合物及其应用
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
KR20260049253A
(ko)
*
|
2023-08-08 |
2026-04-13 |
미라티 테라퓨틱스, 인크. |
악성 말초 신경초 종양을 치료하는 방법 및 조성물
|
|
IL327063A
(en)
*
|
2023-09-15 |
2026-05-01 |
Ideaya Biosciences Inc |
Methods for treating MAT2A-related diseases
|
|
CN121866246A
(zh)
*
|
2023-09-20 |
2026-04-14 |
西藏海思科制药有限公司 |
一种含氰基的杂环化合物及其用途
|
|
IL327306A
(en)
|
2023-10-12 |
2026-05-01 |
Revolution Medicines Inc |
Macrocyclic RAS inhibitors
|
|
CN121889382A
(zh)
*
|
2023-11-08 |
2026-04-17 |
北京泰德制药股份有限公司 |
Prmt5抑制剂及其制备方法
|
|
TW202532070A
(zh)
*
|
2023-12-01 |
2025-08-16 |
大陸商上海翰森生物醫藥科技有限公司 |
四並環類衍生物抑制劑、其製備方法和應用
|
|
WO2025157286A1
(zh)
*
|
2024-01-26 |
2025-07-31 |
上海湃隆生物科技有限公司 |
包含prmt5抑制剂和mat2a抑制剂的药物组合物
|
|
WO2025166308A1
(en)
*
|
2024-01-31 |
2025-08-07 |
Tango Therapeutics, Inc. |
Crystalline forms, pharmaceutical compositions and methods of use thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025217297A1
(en)
*
|
2024-04-09 |
2025-10-16 |
Tango Therapeutics, Inc. |
Prmt5 inhibitors for use in methods of treating mta-accumulating cancer
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025250569A1
(en)
*
|
2024-05-29 |
2025-12-04 |
Amgen Inc. |
Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|